Literature DB >> 10885828

Pharmacological issues relating to viral resistance.

D J Back1.   

Abstract

Anti-HIV drug regimens can fail for a number of reasons including virological resistance, difficulties of adherence and poor tolerability. However, this brief review focuses on the development of "pharmacological" resistance as an area of great importance in drug failure. For nucleoside reverse transcriptase inhibitors (NRTIs) this is related to the possible down-regulation of the intracellular phosphorylation of an NRTI with time. For protease inhibitors the concern is cells expressing transmembrane energy-dependent transporters (such as p-glycoprotein, p-gp; or multi-drug resistance protein, MRP) which efflux drug (particularly protease inhibitors) out of the cell so that intracellular concentrations of drug are insufficient for antiviral effect.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10885828     DOI: 10.1007/BF02561671

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  The bottleneck in AZT activation.

Authors:  A Lavie; I Schlichting; I R Vetter; M Konrad; J Reinstein; R S Goody
Journal:  Nat Med       Date:  1997-08       Impact factor: 53.440

2.  Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

Authors:  R S Hogg; K V Heath; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

Review 3.  Biochemistry of multidrug resistance mediated by the multidrug transporter.

Authors:  M M Gottesman; I Pastan
Journal:  Annu Rev Biochem       Date:  1993       Impact factor: 23.643

4.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

5.  Is P-glycoprotein a sufficient marker for multidrug resistance in vivo? Immunohistochemical staining for P-glycoprotein in children and adult leukemia: correlation with clinical outcome.

Authors:  S Kaczorowski; M Ochocka; M Kaczorowska; R Aleksandrowicz; M Matysiakl; M Karwacki
Journal:  Leuk Lymphoma       Date:  1995-12

6.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

Authors:  C G Lee; M M Gottesman; C O Cardarelli; M Ramachandra; K T Jeang; S V Ambudkar; I Pastan; S Dey
Journal:  Biochemistry       Date:  1998-03-17       Impact factor: 3.162

7.  Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.

Authors:  W Y Gao; D G Johns; H Mitsuya
Journal:  Mol Pharmacol       Date:  1994-10       Impact factor: 4.436

8.  Decreased thymidine kinase levels in peripheral blood cells from HIV-seropositive individuals: implications for zidovudine metabolism.

Authors:  B Jacobsson; S Britton; Q He; A Karlsson; S Eriksson
Journal:  AIDS Res Hum Retroviruses       Date:  1995-07       Impact factor: 2.205

9.  Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters.

Authors:  R V Srinivas; D Middlemas; P Flynn; A Fridland
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: analysis of lymphocyte surface expression and drug-unrelated function.

Authors:  M B Lucia; R Cauda; A L Landay; W Malorni; G Donelli; L Ortona
Journal:  AIDS Res Hum Retroviruses       Date:  1995-08       Impact factor: 2.205

View more
  2 in total

Review 1.  The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions.

Authors:  Lawrence M DuBuske
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

2.  Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection.

Authors:  Jayati Mookerjee Basu; Ananda Mookerjee; Rajdeep Banerjee; Manik Saha; Subhankar Singh; Ksudiram Naskar; Gayetri Tripathy; Prabhat K Sinha; Krishna Pandey; Shyam Sundar; Sanjeev Bimal; Pradip K Das; Soumitra K Choudhuri; Syamal Roy
Journal:  Antimicrob Agents Chemother       Date:  2007-12-03       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.